Tech Company Financing Transactions
Novelion Therapeutics Funding Round
Novelion Therapeutics closed a $22 million Series A financing round on 6/14/2006. Backers included Advent International, Alta Partners and Index Ventures.
Transaction Overview
Company Name
Announced On
6/14/2006
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds will fund Phase II development of its lead dyslipidemia drug, AEGR 733.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
510 West Georgia St. 1800
Vancouver BC, V6B 0M3
USA
Vancouver BC, V6B 0M3
USA
Phone
Website
Email Address
Overview
Novelion Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sandford Smith
Chief Financial Officer
Michael Price
Chief Operating Officer
Jeffrey Hackman
VP - General Counsel
Ben Harshbarger
VP - Human Resources
Linda Buono
VP - R & D
Murray Stewart
Browse more venture capital transactions:
Prev: 6/13/2006: Oddcast venture capital transaction
Next: 6/14/2006: Aveksa venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs